Xconomy’s Digital Events →
Matthew Scholz is the CEO of Immusoft, a (currently) Seattle based biotech startup that is commercializing technology to program the human immune system.
If Seattle is to occupy a future place of dominance in the biotech world, it must foster more of an “incubator” culture. There is a “valley of death” between the well-funded... Read more »
Xconomy Insight · Special Report
Industry experts explain what it takes to launch a new biotech company
From Our Partners · Special Report
Advice for funding and future transformational opportunities
Sponsored · Video
A Fireside Chat with Biocom President & CEO Joe Panetta
© 2007-2021, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.